Payment overview · 2025
General Payments
$653.66
27 reported records · 14 companies
Healthcare provider profile · identity verified
Kyle Lance Caulfield, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HAMMOND, LA · NPI 1164420162
Verified facts
What the public records show
CMS Open Payments records show Kyle Lance Caulfield, MD received $653.66 in general payments during 2025 across 27 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Mounjaro, Nurtec Odt, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 346 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nurtec Odt by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $239.01 | 36.6% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $108.04 | 16.5% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $43.40 | 6.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.62 | 5.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.80 | 5.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.68 | 5.2% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $31.87 | 4.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.26 | 3.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.30 | 3.0% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $18.08 | 2.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.84 | 2.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.30 | 2.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.91 | 2.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.55 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $653.66 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $124.01 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $115.00 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $108.04 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $86.76 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $51.52 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $43.40 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.80 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $31.87 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 134 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 160 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
134 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
144 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
160 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
346 | 60 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 859 | 202 |
| Levothyroxine Sodium | Levothyroxine Sodium | 692 | 141 |
| Alprazolam | Alprazolam | 670 | 93 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 668 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 608 | 146 |
| Atorvastatin Calcium | Atorvastatin Calcium | 446 | 94 |
| Losartan Potassium | Losartan Potassium | 419 | 83 |
| Gabapentin | Gabapentin | 406 | 83 |
| Furosemide | Furosemide | 371 | 92 |
| Eliquis | Apixaban | 346 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 329 | 82 |
| Trazodone Hcl | Trazodone Hcl | 286 | 61 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 266 | 64 |
| Metformin Hcl | Metformin Hcl | 265 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 257 | 68 |
| Prednisone | Prednisone | 253 | 146 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 241 | 38 |
| Lisinopril | Lisinopril | 199 | 54 |
| Tramadol Hcl | Tramadol Hcl | 195 | 41 |
| Donepezil Hcl | Donepezil Hcl | 193 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 190 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 182 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 173 | 27 |
| Meloxicam | Meloxicam | 171 | 46 |
| Sertraline Hcl | Sertraline Hcl | 171 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 161 | 35 |
| Mounjaro | Tirzepatide | 160 | 19 |
| Jardiance | Empagliflozin | 144 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 38 |
| Clonazepam | Clonazepam | 141 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 46 |
| Farxiga | Dapagliflozin Propanediol | 134 | 24 |
| Mirtazapine | Mirtazapine | 134 | 19 |
| Myrbetriq | Mirabegron | 131 | 13 |
| Memantine Hcl | Memantine Hcl | 130 | 21 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 129 | 15 |
| Cefdinir | Cefdinir | 123 | 99 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 38 |
| Methylprednisolone | Methylprednisolone | 116 | 89 |
| Simvastatin | Simvastatin | 116 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 114 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 114 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 31 |
| Carvedilol | Carvedilol | 109 | 26 |
| Lorazepam | Lorazepam | 108 | 19 |
| Carisoprodol | Carisoprodol | 105 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 27 |
| Potassium Chloride | Potassium Chloride | 101 | 23 |
| Levetiracetam | Levetiracetam | 98 | 16 |
| Allopurinol | Allopurinol | 94 | 23 |
| Spironolactone | Spironolactone | 94 | 17 |
| Glimepiride | Glimepiride | 91 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 21 |
| Januvia | Sitagliptin Phosphate | 88 | 13 |
| Omeprazole | Omeprazole | 84 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 63 |
| Montelukast Sodium | Montelukast Sodium | 80 | 14 |
| Levofloxacin | Levofloxacin | 79 | 58 |
| Temazepam | Temazepam | 78 | 12 |
| Azithromycin | Azithromycin | 77 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 22 |
| Nifedipine Er | Nifedipine | 73 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 18 |
| Linzess | Linaclotide | 68 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 13 |
| Fluconazole | Fluconazole | 65 | 34 |
| Lactulose | Lactulose | 64 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 62 | 29 |
| Propranolol Hcl | Propranolol Hcl | 62 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 58 | 11 |
| Ibuprofen | Ibuprofen | 56 | 18 |
| Ozempic | Semaglutide | 56 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 55 | suppressed |
| Celecoxib | Celecoxib | 55 | 21 |
| Ondansetron Odt | Ondansetron | 55 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 54 | suppressed |
| Hydrocortisone | Hydrocortisone | 53 | 20 |
| Famotidine | Famotidine | 52 | suppressed |
| Sucralfate | Sucralfate | 52 | 12 |
| Metformin Hcl Er | Metformin Hcl | 50 | 13 |
| Diazepam | Diazepam | 49 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Olanzapine | Olanzapine | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Nystatin | Nystatin | 44 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | suppressed |
| Valsartan | Valsartan | 43 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 28 |
| Divalproex Sodium | Divalproex Sodium | 40 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Eszopiclone | Eszopiclone | 39 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Amoxicillin | Amoxicillin | 37 | 20 |
| Irbesartan | Irbesartan | 37 | suppressed |
| Novolog Flexpen | Insulin Aspart | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Atenolol | Atenolol | 35 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Mupirocin | Mupirocin | 32 | 21 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 31 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 31 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 23 |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 12 |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | 14 |
| Cephalexin | Cephalexin | 24 | 19 |
| Cholestyramine Light | Cholestyramine | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 23 | 23 |
| Pregabalin | Pregabalin | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Daptomycin | Daptomycin | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Rhopressa | Netarsudil Mesylate | 12 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $653.66 · 27 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AUSTEDO XR, BREZTRI, Dexcom G6 Transmitter, FARXIGA, FUROSCIX, GEMTESA, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, REXULTI, SPRAVATO, VOQUEZNA, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error